Recent articles
Here's Why Fluidigm Stock Lost as Much as 54.2% Today
The lab instrument developer was crushed after a disappointing quarterly report. Investors are right to worry.
Here's Why Chemours Rose as Much as 13.3% Today
The titanium dioxide manufacturer performed well in the third quarter despite a challenging market environment.
Here's Why Myriad Genetics Shares Got Crushed Today
The genetic-testing leader just whacked its fiscal full-year 2020 guidance.
1 Alarming Stat for America's Coal Industry
Coal-fired power plants had a pretty bad summer, suggesting the record pace of retirements will continue for the foreseeable future.
Is Your Portfolio Prepared for Single-Use Plastic Bans?
Cities and countries around the globe are outlawing wasteful plastic products and promising to hold manufacturers accountable. That creates risks and opportunities for investors.
Puma Biotechnology's Next Update Is an Important One
Investors are eager to see how Nerlynx is faring in light of a high discontinuation rate among patients and a recent label supplement that could reverse the trend.
Illumina's Next Big Move: Distributed Diagnostics
It's an inevitable step in the evolution of healthcare -- and one that could help Illumina grow into its premium valuation.
Repligen Exits Third Quarter Armed With a $500 Million War Chest
The company, which has been built on opportunistic acquisitions, entered the final stretch of 2019 with a record level of cash to deploy.
Here's Why Enphase Energy Is Collapsing Today
It's difficult to believe, but Wall Street is worried that growth may be weakening.
Enphase Energy Expects Its First $200 Million Quarter in 2019
The business is rolling heading into 2020, but Wall Street appears to be worried over something out of the company's control.
2 Renewable Energy Trends to Watch in the Final Months of 2019
To rapidly decarbonize the global economy, wind and solar need some help. These two technologies could provide it.
NeoGenomics Pours Money Into Next-Generation Sequencing Capabilities
The cancer-focused genetic testing service provider upgraded its offerings to provide higher-quality data from the same biological samples. That should keep growth humming along.
Here's Why NeoGenomics Rose as Much as 11.2% Today
An excellent third-quarter performance for the genetic testing company has investors cheering.
Here's Why U.S. Silica Stock Fell Over 38% Today
Investors can't take the weakness in frack sand markets any longer, but the industrial segment is looking wobbly, too.
Here's Why Beyond Meat Is Getting Crushed Today
The animal-free protein developer announced solid third-quarter 2019 results and is now profitable, but investors wanted even more.
Is Gossamer Bio a Buy?
Fresh off an initial public offering, the pharmaceutical company has taken investors on a wild ride.
Albemarle Resets Investor Expectations Lower Through 2020
The lithium producer reduced full-year 2019 guidance and expects pricing pressure to remain in 2020, but better days are ahead.
Permian Basin Keeps Powering Xcel Energy's Growth
The company's operations in New Mexico and Texas have been responsible for all earnings growth in 2019. Investors can thank the oil and gas industry.
Here's Why Albemarle Fell as Much as 10% Today
The lithium producer cut 2019 guidance and told investors that they'll have to endure tough times into 2020.
Livent's Move for Lithium Market Share Is Crushing Its Stock
At a time when other major lithium producers are slashing production growth plans, Livent is plowing full steam ahead. Wall Street hates the idea, but it could pay off.